Skip to content

Study · Animal study (in vivo) · mouse · 2023

9 results

Dulaglutide Protects Mice against Diabetic Sarcopenia-Mediated Muscle Injury by Inhibiting Inflammation and Regulating the Differentiation of Myoblasts.

Deng F, Wu W, Fan X, Zhong X, Wang N, Wang Y, Pan T, Du Y

International journal of endocrinology7 Aug 2023Cited by 24 (Europe PMC)

PMID37584041 (opens in a new tab)PMCIDPMC10425251 (opens in a new tab)DOI10.1155/2023/9926462 (opens in a new tab)PepBankPUB-37584041
Download PDFPubMedAsk about this study
Jump to 9 results

Summary

BackgroundType 2 diabetes mellitus increases the risk of sarcopenia, which is characterized by decreased muscle mass, strength, and function. However, there are no effective drugs to treat diabetic sarcopenia, and its underlying mechanism remains unknown. Here, we aimed to determine whether the GLP-1 receptor agonist (GLP-1RA) dulaglutide (Dul) affects the progression of diabetic sarcopenia.Methodsdb/db mice were injected intraperitoneally with 0.6 mg/kg dulaglutide for 10 weeks. Mouse muscle tissues were then pathologically evaluated and stained with F4/80 or MPO to detect macrophages and neutrophils, respectively. In addition, inflammatory factors and FNDC5 in the muscle tissues were detected using qRT-PCR. Moreover, C2C12 cells were induced to enable their differentiation into skeletal muscle cells, and muscle factor levels were then detected. Furthermore, changes in muscle factor levels were detected at various glucose concentrations (11 mM, 22 mM, and 44 mM).ResultsIn vivo, dulaglutide alleviated muscle tissue injury; reduced levels of the inflammatory factors, IL-1β, IL-6, CCL2, and CXCL1; and reversed the level of FNDC5 in the muscle tissues of db/db mice. In vitro, a C2C12 cell differentiation model was established through the observation of cell morphology and determination of myokine levels. Upon stimulation with high glucose, the differentiation of C2C12 cells was inhibited. Dulaglutide improved this inhibitory state by upregulating the levels of both FNDC5 mRNA and protein.ConclusionsTreatment with the GLP-1RA dulaglutide protects db/db mice against skeletal muscle injury by inhibiting inflammation and regulating the differentiation of myoblasts. High glucose inhibited the differentiation of C2C12 cells and decreased the mRNA and protein levels of myokines. Dulaglutide could reverse the differentiation state induced in C2C12 cells by high glucose.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, dulaglutide alleviated muscle tissue injury.

    In plain wordsIn mice with diabetes, dulaglutide reduced muscle tissue injury.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseMuscle tissue injury
    Study

    mousen: not reported in source

    db/db mice
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    0.6 mg/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    In vivo, dulaglutide alleviated muscle tissue injury; reduced levels of the inflammatory factors, IL-1β, IL-6, CCL2, and CXCL1; and reversed the level of FNDC5 in the muscle tissues of db/db mice.
    1 context sentence
    Summary · context
    db/db mice were injected intraperitoneally with 0.6 mg/kg dulaglutide for 10 weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, dulaglutide reduced muscle IL-1β levels.

    In plain wordsIn mice with diabetes, dulaglutide reduced the muscle inflammation marker IL-1β.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseMuscle IL-1β
    Study

    mousen: not reported in source

    db/db mice
    Outcome group
    Inflammation markers · Musculoskeletal
    Studied dose
    0.6 mg/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    In vivo, dulaglutide alleviated muscle tissue injury; reduced levels of the inflammatory factors, IL-1β, IL-6, CCL2, and CXCL1; and reversed the level of FNDC5 in the muscle tissues of db/db mice.
    1 context sentence
    Summary · context
    db/db mice were injected intraperitoneally with 0.6 mg/kg dulaglutide for 10 weeks.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, dulaglutide reduced muscle IL-6 levels.

    In plain wordsIn mice with diabetes, dulaglutide reduced the muscle inflammation marker IL-6.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseMuscle IL-6
    Study

    mousen: not reported in source

    db/db mice
    Outcome group
    Inflammation markers · Musculoskeletal
    Studied dose
    0.6 mg/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    In vivo, dulaglutide alleviated muscle tissue injury; reduced levels of the inflammatory factors, IL-1β, IL-6, CCL2, and CXCL1; and reversed the level of FNDC5 in the muscle tissues of db/db mice.
    1 context sentence
    Summary · context
    db/db mice were injected intraperitoneally with 0.6 mg/kg dulaglutide for 10 weeks.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, dulaglutide reduced muscle CCL2 levels.

    In plain wordsIn mice with diabetes, dulaglutide reduced the muscle inflammation marker CCL2.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseMuscle CCL2
    Study

    mousen: not reported in source

    db/db mice
    Outcome group
    Inflammation markers · Musculoskeletal
    Studied dose
    0.6 mg/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    In vivo, dulaglutide alleviated muscle tissue injury; reduced levels of the inflammatory factors, IL-1β, IL-6, CCL2, and CXCL1; and reversed the level of FNDC5 in the muscle tissues of db/db mice.
    1 context sentence
    Summary · context
    db/db mice were injected intraperitoneally with 0.6 mg/kg dulaglutide for 10 weeks.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, dulaglutide reduced muscle CXCL1 levels.

    In plain wordsIn mice with diabetes, dulaglutide reduced the muscle inflammation marker CXCL1.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseMuscle CXCL1
    Study

    mousen: not reported in source

    db/db mice
    Outcome group
    Inflammation markers · Musculoskeletal
    Studied dose
    0.6 mg/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    In vivo, dulaglutide alleviated muscle tissue injury; reduced levels of the inflammatory factors, IL-1β, IL-6, CCL2, and CXCL1; and reversed the level of FNDC5 in the muscle tissues of db/db mice.
    1 context sentence
    Summary · context
    db/db mice were injected intraperitoneally with 0.6 mg/kg dulaglutide for 10 weeks.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, dulaglutide reversed the muscle FNDC5 level alteration, without an explicit direction reported.

    In plain wordsIn mice with diabetes, dulaglutide reversed a change in muscle FNDC5 levels. The abstract did not specify the direction.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedMuscle FNDC5
    Study

    mousen: not reported in source

    db/db mice
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    0.6 mg/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    In vivo, dulaglutide alleviated muscle tissue injury; reduced levels of the inflammatory factors, IL-1β, IL-6, CCL2, and CXCL1; and reversed the level of FNDC5 in the muscle tissues of db/db mice.
    1 context sentence
    Summary · context
    db/db mice were injected intraperitoneally with 0.6 mg/kg dulaglutide for 10 weeks.
  7. 07LabIn vitro (cells)Efficacy outcome

    In high-glucose C2C12 cells, dulaglutide improved inhibited differentiation.

    In plain wordsIn cells exposed to high glucose, dulaglutide improved inhibited muscle cell differentiation.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseCell differentiation
    Study

    n: not reported in source

    High-glucose C2C12 differentiation model
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Dulaglutide improved this inhibitory state by upregulating the levels of both FNDC5 mRNA and protein.
    1 context sentence
    Summary · context
    Upon stimulation with high glucose, the differentiation of C2C12 cells was inhibited.
  8. 08LabIn vitro (cells)Mechanism

    In high-glucose C2C12 cells, dulaglutide increased FNDC5 mRNA levels.

    In plain wordsIn cells exposed to high glucose, dulaglutide increased FNDC5 gene activity.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseFNDC5 mRNA
    Study

    n: not reported in source

    High-glucose C2C12 differentiation model
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Dulaglutide improved this inhibitory state by upregulating the levels of both FNDC5 mRNA and protein.
    1 context sentence
    Summary · context
    Upon stimulation with high glucose, the differentiation of C2C12 cells was inhibited.
  9. 09LabIn vitro (cells)Mechanism

    In high-glucose C2C12 cells, dulaglutide increased FNDC5 protein levels.

    In plain wordsIn cells exposed to high glucose, dulaglutide increased FNDC5 protein levels.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseFNDC5 protein
    Study

    n: not reported in source

    High-glucose C2C12 differentiation model
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Dulaglutide improved this inhibitory state by upregulating the levels of both FNDC5 mRNA and protein.
    1 context sentence
    Summary · context
    Upon stimulation with high glucose, the differentiation of C2C12 cells was inhibited.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.